News & Publications Careers Contact Us ABOUT NABRIVA PIPELINE & RESEARCH FOR INVESTORS Driven to Deliver Innovative Treatments for Patients With Infectious Diseases Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections. Learn More PIPELINE & RESEARCH Learn About Our Novel Antibiotic Candidates See Pipeline FOR INVESTORS Find Shareholder News, Events, & More Visit Investors Center CAREERS Join Our Growing Team at Nabriva View Jobs Collaborate With Us We’re developing innovative therapies that have the potential to transform the lives of people with infectious diseases, and our current platform is just the beginning. We actively seek collaborators and licensing opportunities focused on the discovery, development, and commercialization of technologies and therapies that address infectious diseases. Contact us to learn more. Contact Us Nabriva Response to COVID-19 Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic. Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics. Xenleta® (lefamulin) may be an alternative regimen for patients in need. Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors. Learn more at www.XENLETA.com. Again, to all the medical professionals, please be safe, take care of yourself and stay well. Best, Ted Schroeder CEO, Nabriva Therapeutics Continue to site In the News Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services 1 2 3 Prev Next Privacy Notice Patents Imprint Disclaimer Contact Us Careers Sitemap © Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland